Key Clinical Updates with HER2-Targeting Therapies - Episode 4

First-Line Treatment Regimens in Metastatic HER2+ Breast Cancer

November 11, 2025

Neil M. Iyengar, MD, Kelly E. McCann, MD, PhD, Kamel Abou Hussein, MD, William J. Gradishar, MD, Sara A. Hurvitz, MD, FACP

Panelists discuss how evolving first-line HER2-targeted combinations are improving outcomes and redefining standards in metastatic breast cancer..

EP. 1: Background Information on Targeted Therapies in Breast Cancer

EP. 2: Clinical Trial Evidence for HER2-Targeted Therapies in Early Breast Cancer

EP. 3: The Role of ADCs in Different Subgroups

Now Viewing

EP. 4: First-Line Treatment Regimens in Metastatic HER2+ Breast Cancer

EP. 5: Treatment Sequencing in Later Lines of Therapy in HER2+ Metastatic Breast Cancer

EP. 6: Additional Data with HER2-Targeted Agents in Metastatic Breast Cancer

EP. 7: Treatment of HER2-Low and Future Therapies in Metastatic Breast Cancer

EP. 8: Disease State Information on TNBC

EP. 9: Exciting New Data for TNBC Therapies

EP. 10: Unmet Needs and Future Outlook for HER2-Targeted Therapies

Panelists discuss how:
Current first-line standards continue to evolve with improved targeted combinations for metastatic HER2-positive breast cancer. They review pivotal data supporting dual HER2 blockade, antibody–-drug conjugates, and optimized chemotherapy backbones. The conversation emphasizes tailoring regimens to patient-specific disease burden, comorbidities, and tolerance profiles. Safety, durability of response, and sequence planning are explored, highlighting the need for continual reassessment as new trials report outcomes.